复发缓解型1型糖尿病
本文报告一例18岁女性,患有Graves病、慢性炎性脱髓鞘性多发性神经根神经病(CIDP)及多种胰岛自身抗体,表现为复发缓解型高血糖。CIDP发作期间出现两次高血糖复发需胰岛素治疗,静脉注射免疫球蛋白(IVIG)改善神经症状后缓解,胰岛素需求消失。作者认为这提供了复发缓解型1型糖尿病与IVIG治疗及胰岛自身免疫调节相关的临床证据。
要点
- CIDP发作期间出现两次高血糖复发需胰岛素治疗,IVIG治疗后缓解且胰岛素需求消失。
- 尽管残留β细胞质量充足,个体仍可出现血糖控制受损。
- β细胞质量与功能之间的分离可能对以β细胞功能为主要终点的免疫干预试验有启示。
核心结论
- 提供复发缓解型1型糖尿病与IVIG治疗及胰岛自身免疫调节相关的临床证据。
- 尽管残留β细胞质量充足,个体仍可出现血糖控制受损。
- β细胞质量与功能之间的分离可能对以β细胞功能而非β细胞质量为主要终点的免疫干预试验有启示。
- 免疫调节可能恢复β细胞功能和血糖控制。
研究设计与样本
- 病例报告:一例18岁女性,患有Graves病、慢性炎性脱髓鞘性多发性神经根神经病(CIDP)及多种胰岛自身抗体。
- 对外周血单个核细胞进行胰岛自身免疫分析。
主要发现
- CIDP发作期间出现两次高血糖复发,需胰岛素治疗,IVIG治疗改善神经症状后缓解。
- 根据胰岛素需求、HbA1c和胰岛自身抗体诊断为1型糖尿病。
- IVIG治疗后胰岛素需求消失,且在CIDP发作期间达到峰值。
- 观察到针对胰岛自身抗原的促炎和抗炎细胞因子反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Type 1 diabetes is believed to be an autoimmune disease associated with irreversible loss of insulin secretory function that follows a chronic progressive course. However, it has been speculated that relapsing/remitting disease progression may occur in type 1 diabetes. METHODS: We report the case of an 18-year-old girl with Graves' disease, chronic inflammatory demyelinating polyneuropathy (CIDP) and multiple islet autoantibodies, presenting with relapsing/remitting hyperglycaemia. Peripheral blood mononuclear cells were analysed for islet autoimmunity. RESULTS: There were two instances of hyperglycaemia relapse during CIDP flare-ups that required insulin therapy and remitted after i.v. immunoglobulin (IVIG) therapy improving neurological symptoms. A diagnosis of type 1 diabetes was assigned on the basis of insulin need, HbA1c and islet autoantibodies. Insulin requirements disappeared following IVIG treatment and peaked during CIDP flare-ups. Pro- and anti-inflammatory cytokine responses were noted against islet autoantigens. CONCLUSIONS/INTERPRETATION: We provide clinical evidence of relapsing/remitting type 1 diabetes associated with IVIG treatment and the regulation of islet autoimmunity. Despite sufficient residual beta cell mass, individuals can experience episodes of impaired glycaemia control. This disconnect between beta cell mass and function highlighted by our case may have implications for the use of beta cell function as the primary endpoint for immune intervention trials aiming to protect beta cell mass rather than function. Immune modulation may restore beta cell function and glycaemic control.
引用
- van Megen KM, Spindler MP, Keij FM, et al. Relapsing/remitting type 1 diabetes. Diabetologia. 2017. PMID: 28835984. doi:10.1007/s00125-017-4403-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。